Bli medlem
Bli medlem

Du är här


Saniona AB: Saniona and Boehringer Ingelheim sign collaboration agreement in schizophrenia


August 29, 2016

* The collaboration aims to develop innovative new treatment options for
patients with schizophrenia
* In the EU, at least 164 million people (38%) suffer from mental health
problems.[i], Overall, the burden of mental illness continues to grow.[ii]

Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies,
and Saniona, a leading biotech company in the field of ion channel drug
discovery, today announced that they have entered into a research
collaboration with the objective to discover and develop novel compounds for
the treatment of schizophrenia. Saniona may receive up to €90 million in
milestone payments including an upfront payment of €5 million upon signing of
the agreement. Furthermore, Saniona is eligible to receive royalties on
worldwide net sales of any resulting products under the collaboration.

The joint research activities aim to identify compounds that could be capable
of restoring brain network activity in patients with schizophrenia. The
neuronal activity in the brain of such patients can be impaired by a
functional imbalance between stimulating (excitatory) and inhibitory
transmission of signals between neurons.

The program aligns with Boehringer Ingelheim's drug discovery strategy for
neuropsychiatric diseases which focuses on systematically investigating
dominant symptom domains and the underlying neurobiology across mental
disorders such as schizophrenia, Alzheimer's disease and depression.

"We are very pleased to be working with Saniona's experienced scientific and
management team and to build on their ion channel drug discovery platform.
Working together and blending our joint expertise and capabilities, we have
the potential to advance new treatment options for schizophrenia" says Clive
R. Wood, Ph.D., Senior Corporate Vice President, Discovery Research at
Boehringer Ingelheim.

Saniona will receive an upfront payment of €5 million upon signing of the
agreement and milestone payments of up to €50 million upon the achievement of
certain research, development and regulatory milestones. In addition, Saniona
is entitled to commercial milestone payments of up to €35 million and tiered
royalties on net sales of any potential products commercialised by Boehringer
Ingelheim as a result of this collaboration. Further financial details were
not disclosed.

"We are delighted to have Boehringer Ingelheim as partner for our
schizophrenia program. My team and I have worked in a long lasting
partnership with Boehringer Ingelheim before and I can truly say that this is
one of our preferred partners. We have a high respect for their diligent and
result oriented R&D operations, their company values, and their effective and
respectful collaborations with partners" says Jørgen Drejer, CEO of Saniona.

Saniona grants Boehringer Ingelheim exclusive worldwide rights to research,
develop, manufacture and commercialise medicines identified through the
collaboration. In addition to upfront and milestone payments and royalties on
net sales, Saniona will receive undisclosed research funding during the joint
research period.

According to the World Health Organisation, mental illness, together with
substance abuse disorders remains the leading cause of disability worldwide.
In the EU, at least 164 million people (38%) suffer from mental health
problems. People with schizophrenia often have problems in many areas of
cognition,[iii]severely impacting their ability to live or function
'normally'. As a consequence, large numbers of people with schizophrenia are
isolated, unemployed and/or homeless.[iv]

For more information, please contact
Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957,

Julia Meyer-Kleinmann, Director Corporate Communications, Boehringer
Ingelheim, Email:, Mobile: +49 178 290

This information is information that Saniona (publ) is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was submitted for
publication, through the agency of the contact person of Saniona set out
above, at 08:30 CET on August 29, 2016.

About Boehringer Ingelheim

Boehringer Ingelheim is one of the world's 20 leading pharmaceutical
companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates
globally through 145 affiliates and a total of some 47,500 employees. The
focus of the family-owned company, founded in 1885, is on researching,
developing, manufacturing and marketing new medications of high therapeutic
value for human and veterinary medicine. Social responsibility is an
important element of the corporate culture at Boehringer Ingelheim. This
includes worldwide involvement in social projects through, for example, the
initiative "Making More Health" while also caring for employees. Respect,
equal opportunity and reconciling career and family form the foundation of
mutual cooperation. The company also focuses on environmental protection and
sustainability in everything it does. In 2015, Boehringer Ingelheim achieved
net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3
per cent of net

About Saniona

Saniona is a research and development company focused on drugs for diseases of
the central nervous system, autoimmune diseases, metabolic diseases and
treatment of pain. The company has a significant portfolio of potential drug
candidates at pre-clinical and clinical stage. The research is focused on ion
channels, which makes up a unique protein class that enables and controls the
passage of charged ions across cell membranes. Saniona has ongoing
collaboration agreements with Upsher-Smith Laboratories, Inc., Productos
Medix, S.A de S.V and Saniona's Boston based spinout Ataxion Inc., which is
financed by Atlas Venture Inc. and Biogen Inc. Saniona is based in
Copenhagen, Denmark, where it has a research center of high international
standard. Saniona is listed at Nasdaq First North Premier and has about 4,400
shareholders. Pareto Securities is Certified Advisor for Saniona. The
company's share is traded under the ticker SANION. Read more
---------------------------------------[i]Wittchen HU,et al
. The size and burden of mental disorders and other disorders of the brain in
Europe 2010.Eur Neuropsychopharmacol
. 2011;21:655-79.
[ii]World Health Organization. Mental disorders. Fact sheet no. 396, updated
October 2015. Available
at: accessed March
[iii]Sheffield JM,et al
. Common and specific cognitive deficits in schizophrenia: relationships to
function.Cogn Affect Behav Neurosci.
[iv]Kooyman I,et al.
Outcomes of public concern in schizophrenia.Br J Psychiatry
. 2007;191(Suppl.50):s29-s36.

20160829 - Saniona - PR - BI Saniona Collab - UK


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Saniona AB via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.